

CLAIMS:

1. The use of an antibody recognising the CDw52 antigen for the manufacture of a medicament for the treatment of multiple sclerosis.

2. The use according to Claim 1 wherein the antibody is a humanised antibody, including CDRs from a mouse or rat antibody combined with framework regions and constant domains from one or more human antibodies.

3. The use according to Claim 2 wherein the antibody is CAMPATH-1H.

4. The use according to any of Claims 1 to 3 wherein the treatment involves daily administration to a patient of a dose of from 1 to 10 mg per day for a period of 1 to 30 days.

5. The use according to any of Claims 1 to 4 wherein the treatment includes administration of a steroid.

6. A therapeutic agent for the treatment of multiple sclerosis comprising an antibody recognising the CDw52 antigen as the active ingredient.

7. A therapeutic agent according to Claim 6 wherein the antibody is a humanised antibody including CDRs from a mouse or rat antibody combined with framework regions and constant domains from one or more human antibodies.

8. A therapeutic agent according to Claim 7 wherein the antibody is CAMPATH-1H.

9. A therapeutic agent according to any of Claims 6 to

8 wherein the daily dose of the antibody is from 1 to 10 mg per day for a period of 1 to 30 days.

10. A therapeutic agent as claimed in any of Claims 6 to 9 wherein the treatment includes administration of a steroid.

11. A method for the treatment of a human subject suffering from multiple sclerosis which comprises administering to the said subject an effective amount of an antibody recognising the CDw52 antigen.

12. A method according to Claim 11 wherein the antibody is a humanised antibody including CDRs from mouse or rat antibody combined with framework regions and constant domains from one or more human antibodies.

13. A method according to Claim 12 wherein the antibody is CAMPATH-1H.

14. A method according to any of Claims 11 to 13 which comprises daily administration of the antibody at a dose of from 1 to 10 mg per day for a period of 1 to 30 days.

15. A method according to any of Claims 11 to 14 which includes administration of an effective amount of a steroid.